EN
登录

Astromech收购Form Bio,在统一战略下整合进化人工智能与基因药物设计

Astromech Acquires Form Bio, Bringing Together Evolutionary AI and Genetic Medicine Design Under One Directive

CISION 等信源发布 2026-11-18 01:00

可切换为仅中文


The combined company takes researchers from evolutionary insight to tested genetic constructs, with applications in human therapeutics, genome engineering, and animal health

合并后的公司助力研究人员将进化洞察转化为经过验证的基因构建体,应用于人类治疗、基因组工程和动物健康领域。

DALLAS

达拉斯

,

,

Nov. 17, 2026

2026年11月17日

/PRNewswire/ -- Astromech, an AI company developing predictive models of biological change, today announced the acquisition of Form Bio in an all-stock transaction valued at $230 million. The acquisition brings Form Bio's intellectual property, selected contracts and assets, and team into Astromech, combining evolutionary modeling with tools for designing genetic medicines and improving their manufacturability..

/美通社/ -- 专注于开发生物变化预测模型的人工智能公司Astromech今日宣布,以全股票交易方式收购Form Bio,交易估值为2.3亿美元。此次收购将Form Bio的知识产权、精选合同与资产以及团队纳入Astromech,从而将进化建模与设计基因药物及提升其可生产性的工具相结合。

Form Bio

生物表格

The combination brings together Astromech's use of evolutionary data to predict biological function with Form Bio's tools for designing genetic medicines that researchers can build and test. DNA sequences conserved across hundreds of millions of years can offer clues to important biological functions and inform therapeutic design.

此次合作将Astromech利用进化数据预测生物功能的能力,与Form Bio用于设计基因药物并供研究人员构建和测试的工具相结合。在数亿年间保守的DNA序列可以为重要的生物功能提供线索,并为治疗设计提供参考。

By connecting those insights with design capabilities, the companies aim to help researchers address quality challenges earlier in development, reducing unwanted components at the design stage and potentially lessening the need for downstream purification. .

通过将上述洞察与设计能力相结合,这些公司旨在帮助研究人员在开发早期应对质量挑战,在设计阶段减少非目标成分,从而可能降低对下游纯化的需求。

Andrew Busey, Form Bio's co-founder and former CEO, has been named Chief AI Officer and Head of Technology at Astromech.

Form Bio 联合创始人兼前首席执行官安德鲁·布西(Andrew Busey)已被任命为 Astromech 的首席人工智能官兼技术负责人。

'Form Bio began by solving the computational challenges discovered from de-extinction and has grown into a company building foundation models for the design of human therapeutics,' said Busey. 'Our work with customers and partners has shaped that evolution, moving us from analyzing biological data to helping design genetic medicines.

“Form Bio 起初致力于解决从物种复生领域发现的计算挑战,如今已发展成为一家为人类疗法设计构建基础模型的公司,”Busey 表示。“我们与客户及合作伙伴的合作塑造了这一演变历程,推动我们从分析生物数据转向协助设计基因药物。

Joining Astromech gives us the opportunity to build on that progress, bringing evolutionary insights into the design decisions we help researchers make.'.

加入Astromech使我们有机会在这一进展的基础上继续推进,将进化论的见解融入我们帮助研究人员做出的设计决策中。

Astromech's models draw on data across species and evolutionary time to understand how biological functions emerged and predict how they may change. Form Bio complements this approach with AI-powered tools for designing genetic medicines, optimizing gene therapy vectors and manufacturing, and assessing genomic quality.

Astromech 的模型利用跨物种和进化时间的数据,以理解生物功能的起源并预测其可能的变化。Form Bio 则通过人工智能驱动的工具来补充这一方法,用于设计基因药物、优化基因治疗载体及生产工艺,并评估基因组质量。

Together, these capabilities aim to help researchers move from identifying evolutionary patterns to designing and testing genetic constructs, with applications in human therapeutics, genome engineering, and animal health..

这些能力共同旨在帮助研究人员从识别进化模式转向设计和测试基因构建体,并应用于人类治疗、基因组工程和动物健康领域。

Form Bio has spent years building foundation models for genomics—learning the grammar of regulatory and coding sequence directly from data, and applying it to the design and development of human therapeutics. Its capabilities support genetic medicine programs at Eli Lilly, Stanford, Coave Therapeutics, Taysha Gene Therapies, and Solid Biosciences..

Form Bio 多年来致力于构建基因组学基础模型——直接从数据中学习调控序列和编码序列的“语法”,并将其应用于人类疗法的设计与开发。其能力支持了礼来公司、斯坦福大学、Coave Therapeutics、Taysha Gene Therapies 以及 Solid Biosciences 的基因药物项目。

Form Bio's work with Cure Rare Disease

Form Bio 与 Cure Rare Disease 的合作

on Duchenne muscular dystrophy increased full-genome content  from 13% to 59% in less than 30 days through promoter sequence-level redesign, with the program has now advanced in vivo preclinical studies. In a separate program, coding-sequence optimization alone increased full-genome content from approximately 2% to approximately 45%, with expression held at baseline..

在杜氏肌营养不良症项目中,通过启动子序列层面的重新设计,全基因组含量在不到30天内从13%提升至59%,该项目目前已进入体内临床前研究阶段。在另一个独立项目中,仅通过编码序列优化,全基因组含量便从约2%提升至约45%,同时表达水平保持在基线状态。

'Form Bio's AI-driven design platform is helping us rapidly evaluate and prioritize gene therapy constructs across multiple programs,' said Adrien Savy, Ph.D., Director of Discovery Science at Coave Therapeutics. In previously published testimonials, Taysha Chief Technology Officer Frederick Porter, Ph.D., highlighted Form Bio's data infrastructure and analysis support for streamlined sample testing, while Solid Biosciences Chief Technology Officer Paul Herzich emphasized its contribution to accelerating therapeutic development toward the clinic..

“Form Bio 的 AI 驱动设计平台正在帮助我们快速评估并优先排序多个项目中的基因治疗构建体,”Coave Therapeutics 发现科学总监 Adrien Savy 博士表示。在此前发布的客户证言中,Taysha 首席技术官 Frederick Porter 博士强调了 Form Bio 的数据基础设施和分析支持如何简化样本测试流程,而 Solid Biosciences 首席技术官 Paul Herzich 则着重指出其在加速疗法向临床推进方面的贡献。

Both companies are part of the Colossal Biosciences ecosystem. Form Bio launched in September 2022, subsequently expanding its computational capabilities into genetic medicine and genome engineering, and has raised more than $40 million in venture financing. Astromech emerged from Colossal's work in comparative genomics, ancient DNA, and computational biology and has raised more than $60 million to date..

这两家公司均属于 Colossal Biosciences 生态系统。Form Bio 于 2022 年 9 月成立,随后将其计算能力扩展至基因医学和基因组工程领域,并已筹集超过 4,000 万美元的风险投资。Astromech 源自 Colossal 在比较基因组学、古 DNA 和计算生物学方面的工作,迄今为止已筹集超过 6,000 万美元。

About Form Bio

关于 Form Bio

Form Bio is a cutting-edge research and discovery platform for individuals and enterprises in life sciences. With the most accessible, comprehensive and collaborative platform in the field, Form Bio empowers scientists to efficiently and effectively harness the proliferation of data and computing power that has transformed the science of discovery.

Form Bio 是一个面向生命科学领域个人和企业的尖端研究与发现平台。凭借该领域最易用、最全面且最具协作性的平台,Form Bio 赋能科学家高效地利用已彻底改变科学发现范式的数据与计算能力的激增优势。

Form Bio offers end-to-end integration of the discovery process with intuitive and easy-to-use software applications, combined with an open and adaptable collaborative environment. Form Bio was developed within Colossal Biosciences and co-founded by Ben Lamm, Andrew Busey, and Kent Wakeford. For more information on Form Bio, please visit .

Form Bio 通过直观易用的软件应用,结合开放且灵活协作的环境,提供发现流程的端到端集成解决方案。Form Bio 孕育于 Colossal Biosciences,由 Ben Lamm、Andrew Busey 和 Kent Wakeford 联合创立。欲了解更多关于 Form Bio 的信息,请访问 。

www.formbio.com

www.formbio.com

.

。

About Astromech

关于Astromech

Astromech is an AI company building a predictive model of biology. Combining deep learning across multi-species genomic and functional data with Bayesian reconstruction of ancestral sequence and regulatory state, Astromech is developing a unified biological intelligence architecture designed to predict how living systems change, identify where they are most vulnerable, and surface the regulatory mechanisms driving both.

Astromech 是一家构建生物学预测模型的人工智能公司。通过将跨物种的基因组和功能数据与深度学习相结合,并辅以祖先序列和调控状态的贝叶斯重建,Astromech 正在开发一种统一的生物智能架构,旨在预测生命系统的变化、识别其最脆弱的环节,并揭示驱动这些变化的调控机制。

Astromech was co-founded by George Church and Ben Lamm and is headquartered in Dallas, Texas.For more information on Astromech, please visit .

Astromech 由乔治·丘奇和本·拉姆联合创立,总部位于德克萨斯州达拉斯。如需了解更多关于 Astromech 的信息,请访问。

www.astromech.com

www.astromech.com

.

。

SOURCE Form Bio

来源:Form Bio